Mara Goldstein
Stock Analyst at Mizuho
(3.94)
# 630
Out of 4,622 analysts
73
Total ratings
48.94%
Success rate
12.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Buy | $26 → $32 | $18.58 | +72.23% | 2 | Jan 31, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $18.37 | +128.63% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $21.29 | +134.85% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $19.13 | +135.23% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $66.12 | +16.45% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $2.75 | +154.55% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $3.09 | +158.90% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $2.31 | +419.48% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $9.74 | +208.01% | 4 | Sep 15, 2023 | |
| VSTM Verastem | Reiterates: Buy | $36 | $2.97 | +1,112.12% | 5 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $1.36 | +341.18% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $6.33 | -44.71% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.23 | +5,230.96% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $2.19 | +813.24% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $109.73 | +18.47% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $1.15 | +73.91% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $4.14 | +189.86% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.87 | +932.58% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $54.88 | -63.56% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.16 | +570.39% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.32 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $6.04 | +131.79% | 1 | Oct 12, 2017 |
Kura Oncology
Jan 31, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $18.58
Upside: +72.23%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $18.37
Upside: +128.63%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $21.29
Upside: +134.85%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $19.13
Upside: +135.23%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $66.12
Upside: +16.45%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $2.75
Upside: +154.55%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $3.09
Upside: +158.90%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $2.31
Upside: +419.48%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $9.74
Upside: +208.01%
Verastem
Aug 29, 2023
Reiterates: Buy
Price Target: $36
Current: $2.97
Upside: +1,112.12%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $1.36
Upside: +341.18%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $6.33
Upside: -44.71%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.23
Upside: +5,230.96%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $2.19
Upside: +813.24%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $109.73
Upside: +18.47%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $1.15
Upside: +73.91%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $4.14
Upside: +189.86%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.87
Upside: +932.58%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $54.88
Upside: -63.56%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.16
Upside: +570.39%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $31.32
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $6.04
Upside: +131.79%